USFDA concludes inspection at Gland Pharma’s Hyderabad facility

25 Jul 2024 Evaluate

United States Food and Drug Administration (USFDA) has concluded the surprise inspection at Gland Pharma’s Dundigal facility at Hyderabad. USFDA has conducted surprise inspection for Good Manufacturing Practices (GMP) between July 22, 2024 and July 25, 2024.

The inspection was concluded with two 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the USFDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1756.55 -31.95 (-1.79%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.